中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 12
Dec.  2018

Advances in the prevention and treatment of posthepatectomy liver failure in patients with primary liver cancer

DOI: 10.3969/j.issn.1001-5256.2018.12.039
Research funding:

 

  • Published Date: 2018-12-20
  • Posthepatectomy liver failure (PHLF) is a major cause of perioperative death after hepatectomy. This article summarizes the current status of research on risk factors contributing to PHLF, prediction methods, preventive measures, and related expert consensus, and it is pointed out that an objective evaluation of liver function before surgery, a reasonable design of the method of liver resection, and accurate operation are the key measures to reduce the incidence rate of PHLF.

     

  • [1] SIEGEL RL, MILLER KD, JEMAL A. Cancer Statistics, 2017[J]. CA Cancer J Clin, 2017, 67 (1) :7-30.
    [2] RAHBARI NN, GARDEN OJ, PADBURY R, et al. Posthepatectomy liver failure:A definition and grading by the International Study Group of Liver Surgery (ISGLS) [J]. Surgery, 2011, 149 (5) :713-724.
    [3] TIMCHENKO NA. Aging and liver regeneration[J]. Trends Endocrinol Metab, 2009, 20 (4) :171-176.
    [4] LITTLE SA, JARNAGIN WR, DEMATTEO RP, et al. Diabetes is associated with increased perioperative mortality but equivalent longterm outcome after hepatic resection for colorectal cancer[J]. J Gastrointest Surg, 2002, 6 (1) :88-94.
    [5] CUCCHETTI A, CESCON M, ERCOLANI G, et al. Safety of hepatic resection in overweight and obese patients with cirrhosis[J].Br J Surg, 2011, 98 (8) :1147-1154.
    [6] El-ZAYADI AR. Heavy smoking and liver[J]. World J Gastroenterol, 2006, 12 (38) :6098-6101.
    [7] REHM J, SAMOKHVALOV AV, SHIELD KD. Global burden of alcoholic liver diseases[J]. J Hepatol, 2013, 59 (1) :160-168.
    [8] HUO YM, ZHU CC, LU TF, et al. Influence of plasma exchange on transplantation related immune function in patients with liver failure[J]. Genet Mol Res, 2015, 14 (3) :8170-8180.
    [9] HUANG G, LAU WY, SHEN F, et al. Preoperative hepatitis B virus DNA level is a risk factor for postoperative liver failure in patients who underwent partial hepatectomy for hepatitis B-related hepatocellular carcinoma[J]. World J Surg, 2014, 38 (9) :2370-2376.
    [10] ZHANG B, XU D, WANG R, et al. Perioperative antiviral therapy improves safety in patients with hepatitis B related HCC following hepatectomy[J]. Int J Surg, 2015, 15:1-5.
    [11] OMATA M, CHENG AL, KOKUDO N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma:a 2017 update[J]. Hepatol Int, 2017, 11 (4) :317-370.
    [12] WU MC, TANG ZY, YE SL, et al. Expert consensus on antiviral therapy to hepatitis B/C virus-related hepatocellular carcinoma[J]. J Clin Hepatol, 2014, 30 (5) :390-395. (in Chinese) 吴孟超, 汤钊猷, 叶胜龙, 等. HBV/HCV相关性肝细胞癌抗病毒治疗专家共识[J].临床肝胆病杂志, 2014, 30 (5) :390-395.
    [13] HERNAEZ R, SOLE, MOREAU R, et al. Acute-on-chronic liver failure:An update[J]. Gut, 2017, 66 (3) :541-553.
    [14] HEIMBACH JK, KULIK LM, FINN RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018, 67 (1) :358-380.
    [15] LIU YL, ZHANG QZ. An excerpt of the Asia Pacific Working Party on nonalcoholic fatty liver disease guidelines 2017[J]. J Clin Hepatol, 2017, 33 (12) :2278-2282. (in Chinese) 刘应莉, 张秋瓒.《2017年亚太工作组非酒精性脂肪性肝病指南》摘译[J].临床肝胆病杂志, 2017, 33 (12) :2278-2282.
    [16] IINABA Y, FURUTANI T, KIMURA K, et al. Growth arrest and DNA damage-inducible 34 regulates liver regeneration in hepatic steatosis in mice[J]. Hepatology, 2015, 61 (4) :1343-1356.
    [17] HO MC, HASEGAWA K, CHEN XP, et al. Surgery for intermediate and advanced hepatocellular carcinoma:A consensus report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2014) [J]. Liver Cancer, 2016, 5 (4) :245-256.
    [18] WAKABAYASHI G, CHERQUI D, GELLER DA, et al. Recommendations for laparoscopic liver resection:A report from the second international consensus conference held in Morioka[J]. Ann Surg, 2015, 261 (4) :619-629.
    [19] SHIBA H, ISHIDA Y, WAKIYAMA S, et al. Negative impact of blood transfusion on recurrence and prognosis of hepatocellular carcinoma after hepatic resection[J]. J Gastrointest Surg, 2009, 13 (9) :1636-1642.
    [20] EMOND JC, RENZ JF, FERRELL LD, et al. Functional analysis of grafts from living donors. Implications for the treatment of older recipients[J]. Ann Surg, 1996, 224 (4) :544-552; discussion552-554.
    [21] Study Group of Surgical Operation, Chinese Society of Surgery, Chinese Medical Association; China International Exchange and Promotive Association for Medical and Health Care; Hepatic Surgery Group, Society of Enhanced Recovery after Surgery. Chinese expert consensus on enhanced recovery after hepatectomy (2017) [J]. J Clin Hepatol, 2017, 33 (10) :1876-1882. (in Chinese) 中华医学会外科学分会外科手术学学组, 中国医疗保健国际交流促进会, 加速康复外科学分会肝脏外科学组.肝切除术后加速康复中国专家共识 (2017版) [J].临床肝胆病杂志, 2017, 33 (10) :1876-1882.
    [22] DONG JH, ZHENG SS, CHEN XP, et al. Consensus on evaluation of hepatic functional reserve before hepatectomy (2011 edition) [J].Chin J Dig Surg, 2011, 10 (1) :20-25. (in Chinese) 董家鸿, 郑树森, 陈孝平, 等.肝切除术前肝脏储备功能评估的专家共识 (2011版) [J].中华消化外科杂志, 2011, 10 (1) :20-25.
    [23] MELLOUL E, HBNER M, SCOTT M, et al. Guidelines for perioperative care for liver surgery:Enhanced Recovery After Surgery (ERAS) society recommendations[J]. World J Surg, 2016, 40 (10) :2425-2440.
    [24] WAI CT, GREENSON JK, FONTANA RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C[J]. Hepatology, 2003, 38 (2) :518-526.
    [25] MALINCHOC M, KAMATH PS, GORDON FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts[J]. Hepatology, 2000, 31 (4) :864-871.
    [26] BROWN RS, LAKE JR. The survival impact of liver transplantation in the MELD era, and the future for organ allocation and distribution[J].Am J Transplant, 2005, 5 (2) :203-204.
    [27] CESCON M, CUCCHETTI A, GRAZI GL, et al. Indication of the extent of hepatectomy for hepatocellular carcinoma on cirrhosis by a simple algorithm based on preoperative variables[J]. Arch Surg, 2009, 144 (1) :57-63; discussion 63.
    [28] JOHNSON PJ, BERHANE S, KAGEBAYASHI C, et al. Assessment of liver function in patients with hepatocellular carcinoma:A new evidence-based approach-the ALBI grade[J]. J Clin Oncol, 2015, 33 (6) :550-558.
    [29] KUO YH, WANG JH, HUNG CH, et al. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use[J]. J Gastroenterol Hepatol, 2017, 32 (12) :1975-1981.
    [30] HIRAOKA A, KUMADA T, MICHITAKA K, et al. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2016, 31 (5) :1031-1036.
    [31] WANG YY, ZHONG JH, SU ZY, et al. Albumin-bilirubin versus Child-Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma[J]. Br J Surg, 2016, 103 (6) :725-734.
    [32] LOAEZA-DEL-CASTILLO A, PAZ-PINEDA F, OVIEDOCáRDENAS E, et al. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis[J]. Ann Hepatol, 2008, 7 (4) :350-357.
    [33] ICHIKAWA T, UENISHI T, TAKEMURA S, et al. A simple, noninvasively determined index predicting hepatic failure following liver resection for hepatocellular carcinoma[J]. J Hepatobiliary Pancreat Surg, 2009, 16 (1) :42-48.
    [34] SHEN SL, FU SJ, CHEN B, et al. Preoperative aspartate aminotransferase to platelet ratio is an independent prognostic factor for hepatitis B-induced hepatocellular carcinoma after hepatic resection[J]. Ann Surg Oncol, 2014, 21 (12) :3802-3809.
    [35] CHENG J, ZHAO P, LIU J, et al. Preoperative aspartate aminotransferase-to-platelet ratio index (APRI) is a predictor on postoperative outcomes of hepatocellular carcinoma[J]. Medicine (Baltimore) , 2016, 95 (48) :e5486.
    [36] MAI RY, YE JZ, WANG YY, et al. Value of albumin-bilirubin score combined with aspartate aminotransferase-to-platelet ratio index in predicting the development of posthepatectomy liver failure in patients with HBV-related hepatocellular carcinoma[J]. J Clin Hepatol, 2018, 34 (2) :292-297. (in Chinese) 麦荣云, 叶甲舟, 王言焱, 等. ALBI联合APRI对HBV相关肝细胞癌肝切除术后肝衰竭发生的预测价值[J].临床肝胆病杂志, 2018, 34 (2) :292-297.
    [37] GEISEL D, LDEMANN L, HAMM B, et al. Imaging-based liver function tests—past, present and future[J]. Rofo, 2015, 187 (10) :863-871.
    [38] PIND ML, BENDTSEN F, KALLEMOSE T, et al. Indocyanine green retention test (ICG-r15) as a noninvasive predictor of portal hypertension in patients with different severity of cirrhosis[J]. Eur J Gastroenterol Hepatol, 2016, 28 (8) :948-954.
    [39] LEVESQUE E, MARTIN E, DUDAU D, et al. Current use and perspective of indocyanine green clearance in liver diseases[J]. Anaesth Crit Care Pain Med, 2016, 35 (1) :49-57.
    [40] National Health and Family Planning Commission of the People's Republic of China. Diagnosis, management, and treatment of hepatocellular carcinoma (V2017) [J]. J Clin Hepatol, 2017, 33 (8) :1419-1431. (in Chinese) 中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范 (2017年版) [J].临床肝胆病杂志, 2017, 33 (8) :1419-1431.
    [41] KUDO M, MATSUI O, IZUMI N, et al. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma:2014 update by the Liver Cancer Study Group of Japan[J]. Liver Cancer, 2014, 3 (3-4) :458-468.
    [42] CHENG XP, ZHAO J, CHEN Y, et al. Comparison of the ability of the PDD-ICG clearance test, CTP, MELD, and MELD-Na to predict short-term and medium-term mortality in patients with decompensated hepatitis B cirrhosis[J]. Eur J Gastroenterol Hepatol, 2016, 28 (4) :444-448.
    [43] OGˇUL H, KANTARU M, GENB, et al. Perfusion CT imaging of the liver:Review of clinical applications[J]. Diagn Interv Radiol, 2014, 20 (5) :379-389.
    [44] BGIN A, MARTEL G, LAPOINTE R, et al. Accuracy of preoperative automatic measurement of the liver volume by CT-scan combined to a 3D virtual surgical planning software (3DVSP) [J]. Surg Endosc, 2014, 28 (12) :3408-3412.
    [45] TONG C, XU X, LIU C, et al. Assessment of liver volume variation to evaluate liver function[J]. Front Med, 2012, 6 (4) :421-427.
    [46] SIRIWARDANA RC, CHAN SC, CHOK KS, et al. Effects of the liver volume and donor steatosis on errors in the estimated standard liver volume[J]. Liver Transpl, 2011, 17 (12) :1437-1442.
    [47] TAMADA T, ITO K, HIGAKI A, et al. Gd-EOB-DTPA-enhanced MR imaging:Evaluation of hepatic enhancement effects in normal and cirrhotic livers[J]. Eur J Radiol, 2011, 80 (3) :e311-e316.
    [48] QIAO YG, AO GK, DONG X, et al. 3. 0 T magnetic resonance Gd-EOB-DTPA MRC application value in bile duct diseases[J].Clin J Med Offic, 2017, 45 (8) :835-839. (in Chinese) 乔远罡, 敖国昆, 董莘, 等. 3. 0T磁共振钆塞酸二钠磁共振胆管造影术在胆管疾病中应用[J].临床军医杂志, 2017, 45 (8) :835-839.
    [49] OKABAYASHIk T, SHIMA Y, MORITA S, et al. Liver function assessment using technetium 99m-galactosyl single-photon emission computed tomography/CT fusion imaging:A prospective trial[J]. J Am Coll Surg, 2017, 225 (6) :789-797.
    [50] KIM YK, NAKANO H, YAMAGUCHI M, et al. Prediction of postoperative decompensated liver function by technetium-99m galactosyl-human serum albumin liver scintigraphy in patients with hepatocellular carcinoma complicating chronic liver disease[J]. Br J Surg, 1997, 84 (6) :793-796.
    [51] SUMIYOSHI T, SHIMA Y, OKABAYASHIk T, et al. Liver function assessment using 99mTc-GSA single-photon emission computed tomography (SPECT) /CT fusion imaging in hilar bile duct cancer:A retrospective study[J]. Surgery, 2016, 160 (1) :118-126.
    [52] EASL clinical practice guidelines:Management of hepatitis C virus infection[J]. J Hepatol, 2014, 60 (2) :392-420.
    [53] POON RT, CHEUNG TT, KWOK PC, et al. Hong Kong consensus recommendations on the management of hepatocellular carcinoma[J]. Liver Cancer, 2015, 4 (1) :51-69.
    [54] WATANABE M, SHIBUYAh A, TAKADA J, et al. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation:A review of 16 patients[J]. Eur J Intern Med, 2010, 21 (4) :333-337.
    [55] Chinese Research Hospital Association, Society for Hepatopancreatobiliary Surgery. Expert consensus on presicion liver resection[J]. Chin J Dig Surg, 2017, 16 (9) :883-893. (in Chinese) 中国研究型医院学会肝胆胰外科专业委员会.精准肝切除术专家共识[J].中华消化外科杂志, 2017, 16 (9) :883-893.
    [56] FANG CH, TAO HS, YANG J, et al. Impact of three-dimensional reconstruction technique in the operation planning of centrally located hepatocellular carcinoma[J]. J Am Coll Surg, 2015, 220 (1) :28-37.
    [57] DIMITROULIS D, TSAPARAS P, VALSAMI S, et al. Indications, limitations and maneuvers to enable extended hepatectomy:Current trends[J]. World J Gastroenterol, 2014, 20 (24) :7887-7893.
    [58] TRESKA V. Methods to increase future liver remnant volume in patients with primarily unresectable colorectal liver metastases:Current state and future perspectives[J]. Anticancer Res, 2016, 36 (5) :2065-2071.
    [59] MANSOUR JC, ALOIA TA, CRANE CH, et al. Hilar cholangiocarcinoma:Expert consensus statement[J]. HPB (Oxford) , 2015, 17 (8) :691-699.
    [60] OGATA S, BELGHITI J, FARGES O, et al. Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma[J]. Br J Surg, 2006, 93 (9) :1091-1098.
    [61] D'HAESE JG, NEUMANN J, WENIGER M, et al. Should ALPPS be used for liver resection in intermediate-stage HCC?[J]. Ann Surg Oncol, 2016, 23 (4) :1335-1343.
    [62] SCHNITZBAUER AA, LANG SA, GOESSMANN H, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings[J]. Ann Surg, 2012, 255 (3) :405-414.
    [63] Chinese Chapter of International Hepato-Pancreato-Biliary Association, Hepatic Surgery Group, Chinese Society of Surgery, Chinese Medical Association. Diagnosis and treatment of cholangiocarcinoma:Surgical expert consensus[J]. J Clin Hepatol, 2015, 31 (1) :12-16. (in Chinese) 国际肝胆胰学会中国分会, 中华医学会外科学分会肝脏外科学组.胆管癌诊断与治疗—外科专家共识[J].临床肝胆病杂志, 2015, 31 (1) :12-16.
    [64] MIYAZAKI M, YOSHITOMI H, MIYAKAWA S, et al. Clinical practice guidelines for the management of biliary tract cancers 2015:The 2nd English edition[J]. J Hepatobiliary Pancreat Sci, 2015, 22 (4) :249-273.
  • Relative Articles

    [1]Jinqiu YANG, Wenxia ZHAO, Cheng ZHOU, Tong LIU. Risk factors for the development of advanced liver fibrosis in nonalcoholic fatty liver disease and establishment of a nomogram model[J]. Journal of Clinical Hepatology, 2024, 40(8): 1579-1584. doi: 10.12449/JCH240812
    [2]Jing KUANG, Shuangqin TENG, Tongtong SHEN, Yiran YAN, Wei WANG, Chuan SHEN, Caiyan ZHAO. Risk factors for portopulmonary hypertension in liver cirrhosis and construction of a predictive model[J]. Journal of Clinical Hepatology, 2024, 40(9): 1802-1806. doi: 10.12449/JCH240914
    [3]Decai KONG, Xiaojing ZHANG, Yangguang YUN, Haoyu DUAN, Junfeng YE. Risk factors for biliary stricture and prognosis after orthotopic liver transplantation[J]. Journal of Clinical Hepatology, 2024, 40(11): 2253-2259. doi: 10.12449/JCH241119
    [4]Mingqiang ZHU, Dashuai YANG, Junpeng PEI, Xiangyun XIONG, Yang SU, Youming DING. Analysis of influencing factors on biliary complications after orthotopic liver transplantation[J]. Journal of Clinical Hepatology, 2023, 39(7): 1627-1632. doi: 10.3969/j.issn.1001-5256.2023.07.017
    [5]Sufang LU, Rui HUANG, Hongli ZHAO, Dandan WANG, Yuzhen DING, Hong ZHOU. Value of a risk assessment model in predicting venous thromboembolism in patients with liver failure after artificial liver support therapy[J]. Journal of Clinical Hepatology, 2023, 39(3): 613-619. doi: 10.3969/j.issn.1001-5256.2023.03.019
    [6]Bingbing ZHU, Jinxiang YANG, Qun ZHANG, Fangyuan GAO, Xianbo WANG. Risk factors for the 90-day prognosis of patients with type I hepatorenal syndrome and establishment of a predictive model[J]. Journal of Clinical Hepatology, 2022, 38(7): 1561-1565. doi: 10.3969/j.issn.1001-5256.2022.07.019
    [7]Perioperative Management Group, Chinese Society of Organ Transplantation, Chinese Medical Association. Expert consensus on perioperative vascular complications for liver transplantation(2021)[J]. Journal of Clinical Hepatology, 2021, 37(9): 2054-2057. doi: 10.3969/j.issn.1001-5256.2021.09.010
    [8]Bing GUO, Mingquan PANG, Xiaolei XU, Junwei HAN, Haijiu WANG. Establishment and evaluation of a nomogram for predicting post-hepatectomy complications in two types of hepatic echinococcosis[J]. Journal of Clinical Hepatology, 2021, 37(11): 2626-2631. doi: 10.3969/j.issn.1001-5256.2021.11.027
    [9]Yun ZHAO, Lijin ZHAO. Research advances in the risk factors for infection after liver transplantation[J]. Journal of Clinical Hepatology, 2021, 37(8): 1957-1962. doi: 10.3969/j.issn.1001-5256.2021.08.046
    [10]Mingwei LI, Jian GAO, Xiangwei ZHAI, Xiangjun QIAN, Xiajie WEN, Mingjie YAO, Zhaojun DUAN, Erjiang ZHAO, Ling ZHANG, Fengmin LU. Construction and analysis of a predictive model for posthepatectomy recurrence in patients with hepatocellular carcinoma based on preoperative CXCL13 measurement[J]. Journal of Clinical Hepatology, 2021, 37(4): 823-828. doi: 10.3969/j.issn.1001-5256.2021.04.020
    [11]Wang Han, Zuo XiangRong, Cao Quan. Predictive factors and interventions for prolonged mechanical ventilation after liver transplantation[J]. Journal of Clinical Hepatology, 2020, 36(7): 1658-1662. doi: 10.3969/j.issn.1001-5256.2020.07.047
    [12]Zhang DaLi, Feng DanNi, Zhang LiJuan, Tang RuJia, He Xi, Zhou Xia, Gao YinJie, Liu ZhenWen, Liu HongLing. Risk factors for recurrence after liver transplantation in patients with hepatocellular carcinoma and their prognosis[J]. Journal of Clinical Hepatology, 2020, 36(9): 1985-1989. doi: 10.3969/j.issn.1001-5256.2020.09.015
    [13]Zheng WeiPing, Shen ZhongYang. Risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma and related control strategies[J]. Journal of Clinical Hepatology, 2019, 35(11): 2391-2395. doi: 10.3969/j.issn.1001-5256.2019.11.003
    [14]Chen Long, Li Yue. The risk factors and prediction systems for posthepatectomy complications[J]. Journal of Clinical Hepatology, 2019, 35(1): 217-221. doi: 10.3969/j.issn.1001-5256.2019.01.048
    [15]Jie EnBo, Xuan FengHui, Sun XiaoDong, Sun DaWei, Lu: GuoYue. An analysis of risk factors for early complications after liver transplantation[J]. Journal of Clinical Hepatology, 2018, 34(6): 1282-1288. doi: 10.3969/j.issn.1001-5256.2018.06.030
    [16]Zhang YinTao, Meng JinYing, Guo ChunGuang, Wang Hua. Risk factors for biliary complications after common bile duct exploration combined with primary suture[J]. Journal of Clinical Hepatology, 2017, 33(2): 304-307. doi: 10.3969/j.issn.1001-5256.2017.02.021
    [17]Wang XinWei, Zhao ZongGang. Risk factors for infectious complications after hepatectomy in patients with intrahepatic bile duct stones[J]. Journal of Clinical Hepatology, 2017, 33(9): 1754-1757. doi: 10.3969/j.issn.1001-5256.2017.09.025
    [18]Wang MingYue, Lu ZhiYan. Imaging evaluation of complications after liver transplantation[J]. Journal of Clinical Hepatology, 2016, 32(12): 2295-2299. doi: 10.3969/j.issn.1001-5256.2016.12.013
    [19]Lu: GuoYue. Risk factors for biliary complications after liver transplantation from donation after cardiac death[J]. Journal of Clinical Hepatology, 2015, 31(12): 2027-2030. doi: 10.3969/j.issn.1001-5256.2015.12.009
    [20]Chen Man, Zhang Xia. Research advances in molecular prediction of recurrence and metastasis of primary liver cancer after liver transplantation[J]. Journal of Clinical Hepatology, 2014, 30(12): 1361-1365. doi: 10.3969/j.issn.1001-5256.2014.12.032
  • Cited by

    Periodical cited type(4)

    1. 李正优,李荷,周俊. 预见性护理结合舒适护理干预在肝移植术后患者中的应用. 西藏医药. 2024(06): 123-125 .
    2. 李珊珊,王媛,高春辉. 早期下床活动对肝移植术后患者胃肠功能及下肢血流的影响. 国际移植与血液净化杂志. 2023(01): 41-44 .
    3. 张欣悦,王海刚,王昊,杨传伟. 他克莫司治疗1例肝移植术后患者的药学监护. 中国医药导报. 2023(14): 183-187 .
    4. 种庚,彭晓春,吴若林,赵红川,邵敏. 成人肝移植术后早期严重并发症相关危险因素分析. 肝胆外科杂志. 2022(06): 454-459 .

    Other cited types(0)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 17.7 %FULLTEXT: 17.7 %META: 74.4 %META: 74.4 %PDF: 7.9 %PDF: 7.9 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 6.2 %其他: 6.2 %其他: 2.2 %其他: 2.2 %Absecon: 0.4 %Absecon: 0.4 %Caserta: 0.4 %Caserta: 0.4 %Seattle: 0.2 %Seattle: 0.2 %[]: 0.9 %[]: 0.9 %上海: 2.4 %上海: 2.4 %中央邦: 1.1 %中央邦: 1.1 %佛山: 0.2 %佛山: 0.2 %兰州: 0.4 %兰州: 0.4 %北京: 3.8 %北京: 3.8 %南京: 0.2 %南京: 0.2 %南宁: 0.4 %南宁: 0.4 %南昌: 2.4 %南昌: 2.4 %南阳: 0.2 %南阳: 0.2 %卡纳塔克: 0.2 %卡纳塔克: 0.2 %台州: 0.2 %台州: 0.2 %合肥: 0.2 %合肥: 0.2 %吉林: 0.7 %吉林: 0.7 %四平: 0.2 %四平: 0.2 %天津: 0.2 %天津: 0.2 %安庆: 0.2 %安庆: 0.2 %安康: 0.2 %安康: 0.2 %宣城: 0.4 %宣城: 0.4 %常德: 0.4 %常德: 0.4 %张家口: 4.2 %张家口: 4.2 %德罕: 0.2 %德罕: 0.2 %成都: 0.7 %成都: 0.7 %扬州: 0.2 %扬州: 0.2 %新乡: 0.2 %新乡: 0.2 %昆明: 2.2 %昆明: 2.2 %杭州: 0.5 %杭州: 0.5 %武汉: 0.5 %武汉: 0.5 %江门: 0.2 %江门: 0.2 %济南: 0.5 %济南: 0.5 %海得拉巴: 0.7 %海得拉巴: 0.7 %温州: 0.4 %温州: 0.4 %湘潭: 0.2 %湘潭: 0.2 %玉林: 0.4 %玉林: 0.4 %罗奥尔凯埃: 0.5 %罗奥尔凯埃: 0.5 %芒廷维尤: 36.2 %芒廷维尤: 36.2 %芝加哥: 0.2 %芝加哥: 0.2 %苏州: 0.2 %苏州: 0.2 %莆田: 0.2 %莆田: 0.2 %莫斯科: 2.0 %莫斯科: 2.0 %葫芦岛: 0.2 %葫芦岛: 0.2 %衡水: 0.4 %衡水: 0.4 %襄阳: 0.2 %襄阳: 0.2 %西宁: 14.6 %西宁: 14.6 %西安: 0.4 %西安: 0.4 %诺沃克: 1.8 %诺沃克: 1.8 %贵阳: 0.4 %贵阳: 0.4 %辽阳: 0.2 %辽阳: 0.2 %运城: 1.6 %运城: 1.6 %遂宁: 0.2 %遂宁: 0.2 %郑州: 0.2 %郑州: 0.2 %镇江: 0.4 %镇江: 0.4 %长春: 3.8 %长春: 3.8 %长沙: 0.5 %长沙: 0.5 %青岛: 0.2 %青岛: 0.2 %香港: 0.4 %香港: 0.4 %马尼拉: 0.2 %马尼拉: 0.2 %其他其他AbseconCasertaSeattle[]上海中央邦佛山兰州北京南京南宁南昌南阳卡纳塔克台州合肥吉林四平天津安庆安康宣城常德张家口德罕成都扬州新乡昆明杭州武汉江门济南海得拉巴温州湘潭玉林罗奥尔凯埃芒廷维尤芝加哥苏州莆田莫斯科葫芦岛衡水襄阳西宁西安诺沃克贵阳辽阳运城遂宁郑州镇江长春长沙青岛香港马尼拉

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1957) PDF downloads(349) Cited by(4)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return